secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001193125-25-126268
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace NAUTILUS study meets safety endpoint; primary efficacy miss but significant in subgroup
--------------------------------------------------------------------------------

- Primary safety endpoint met: low rate of serious adverse events related to device/implant procedure.
- Primary efficacy endpoint (time to second GTC seizure) not statistically significant in overall population.
- Statistically significant response in subgroup with lower baseline GTC seizure frequency, representing majority of participants.
- Secondary metrics (median seizure reduction, responder rates, seizure-free days) showed clinically meaningful improvements.
- Full-year 2025 financial guidance reaffirmed; CEO notes base business growing >20% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525126268/0001193125-25-126268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000119312525126268/d909963d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-126268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer